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Purpose: Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-oesophageal inflammation, an accepted risk factor for cancer. We explore whether use of these medications is associated with an increased risk of gastro-oesophageal cancer.

Methods: A nested case-control study was conducted using the Primary Care Clinical Information Unit Research (PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 1999 and 2011 were matched to up to five controls based on age, gender, year of diagnosis and general practice. Medication use was ascertained using electronic prescribing records. Conditional logistic regression was used to calculate odds ratios (ORs) for the association between medication use and cancer risk after adjustment for comorbidities and other medication use. 

Results: A similar proportion of gastro-oesophageal cancer cases received bisphosphonates (3.9% vs. 3.5%), tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) compared with the controls.  The adjusted ORs for the association between gastro-oesophageal cancer and bisphosphonates, tetracycline and spironolactone were 1.05 (95% CI: 0.85, 1.31), 0.99 (95% CI: 0.84, 1.17) and 1.04 (95% CI: 0.73, 1.49). Further analysis revealed bisphosphonates were associated with increased oesophageal cancer risk (1.34, 95% CI: 1.03, 1.74) but reduced gastric cancer risk (0.71, 95% CI: 0.49, 1.03), although there was no obvious dose-response relationship.





Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-oesophageal inflammation, an accepted risk factor for cancer. However, evidence on the effect of these medications on gastro-oesophageal cancer risk are mixed or missing entirely. Therefore, we conducted a nested case-control study using the Primary Care Clinical Information Unit Research (PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 1999 and 2011 were matched to up to five controls based on age, gender, year of diagnosis and general practice. Medication use was ascertained using electronic prescribing records. Conditional logistic regression was used to calculate odds ratios (ORs) for the association between medication use and cancer risk after adjustment for comorbidities and other medication use. 






Oesophageal and gastric cancer are among the most common cancers in the world with around 456,000 and 952,000 new cases diagnosed annually. HYPERLINK \l "_ENREF_1" \o "GLOBOCAN, 2012 #87"  ADDIN EN.CITE <EndNote><Cite><Author>GLOBOCAN</Author><Year>2012</Year><RecNum>87</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1478178490">87</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>GLOBOCAN</author></authors></contributors><titles><title>Estimated Cancer Incidence, Mortaility and Prevelence Worldwide in 2012</title></titles><number>03/11/2016</number><dates><year>2012</year></dates><urls></urls></record></Cite></EndNote>1 Prognosis is extremely poor, even in OECD countries such as the UK, where around 55% of patients die within one year of diagnosis. HYPERLINK \l "_ENREF_2" \o "Office for National Statistics, 2016 #50"  ADDIN EN.CITE <EndNote><Cite><Author>Office for National Statistics</Author><Year>2016</Year><RecNum>50</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1475838783">50</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Office for National Statistics,</author></authors></contributors><titles><title>Cancer survival in England: Patients diagnosed between 2010 and 2014 and followed up to 2015</title></titles><volume>2016</volume><number>07/10/2016</number><dates><year>2016</year></dates><urls><related-urls><url>http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinenglandadultsdiagnosed/2010and2014andfollowedupto2015#5-year-survival</url></related-urls></urls></record></Cite></EndNote>2 Those who survive suffer marked reduction in their quality of life during treatment and recovery. ADDIN EN.CITE 3-5 Inflammation is a well-established risk factor for cancer and various mechanisms have been proposed to explain this connection. ADDIN EN.CITE ,  Several studies have demonstrated that patients with reflux oesophagitis have much higher oesophageal cancer risk ADDIN EN.CITE 8, most likely through the Barrett’s pathway. ADDIN EN.CITE ,  It is also well recognised that chronic gastric inflammation, for example due to H. pylori infection, may progress to atrophy (e.g. ulceration), metaplasia, dysplasia, and gastric cancer. ADDIN EN.CITE , 

Bisphosphonates, tetracyclines and spironolactone are widely used medications with main indications of osteoporosis, infections/acne/rosacea and hypertension/cardiac failure, respectively. During 2015, approximately 8.2, 3.2 and 2.5 million were prescribed by English general practitioners. HYPERLINK \l "_ENREF_13" \o "Powell-Smith, 2016 #2"  ADDIN EN.CITE <EndNote><Cite><Author>Powell-Smith</Author><Year>2016</Year><RecNum>2</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1474903061">2</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Powell-Smith, A.</author><author>Goldacre, B.</author></authors></contributors><titles><title>OpenPrescribing.net</title></titles><dates><year>2016</year></dates><urls></urls><custom1>2016</custom1><custom2>26/09/2016</custom2></record></Cite></EndNote>13 Long-term usage of these medications is common; for example the anti-fracture effects of some bisphosphonates are only realised after 36 months ADDIN EN.CITE 14 and tetracycline treatment for acne can last indefinitely. HYPERLINK \l "_ENREF_15" \o "Dreno, 2004 #4"  ADDIN EN.CITE <EndNote><Cite><Author>Dreno</Author><Year>2004</Year><RecNum>4</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1474903134">4</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dreno, B.</author><author>Bettoli, V.</author><author>Ochsendorf, F.</author><author>Layton, A.</author><author>Mobacken, H.</author><author>Degreef, H.</author></authors></contributors><auth-address>Department of Dermatology, Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France. brigitte.dreno@wanadoo.fr</auth-address><titles><title>European recommendations on the use of oral antibiotics for acne</title><secondary-title>Eur J Dermatol</secondary-title><alt-title>European journal of dermatology : EJD</alt-title></titles><periodical><full-title>Eur J Dermatol</full-title><abbr-1>European journal of dermatology : EJD</abbr-1></periodical><alt-periodical><full-title>Eur J Dermatol</full-title><abbr-1>European journal of dermatology : EJD</abbr-1></alt-periodical><pages>391-9</pages><volume>14</volume><number>6</number><edition>2004/11/27</edition><keywords><keyword>Acne Vulgaris/*drug therapy/pathology</keyword><keyword>Administration, Oral</keyword><keyword>Anti-Bacterial Agents/administration &amp; dosage/*therapeutic use</keyword><keyword>Europe</keyword><keyword>Humans</keyword><keyword>Severity of Illness Index</keyword></keywords><dates><year>2004</year><pub-dates><date>Nov-Dec</date></pub-dates></dates><isbn>1167-1122 (Print)&#xD;1167-1122</isbn><accession-num>15564203</accession-num><urls><related-urls><url>http://www.jle.com/fr/revues/ejd/e-docs/european_recommendations_on_the_use_of_oral_antibiotics_for_acne__263963/article.phtml</url></related-urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>15  Each of these medications has been associated with increased risk of gastro-oesophageal inflammation.  Specifically, bisphosphonates have been shown in case reports to cause severe esophagitis including inflammation and thickening of the oesophageal wall ADDIN EN.CITE ,  Tetracyclines have also been shown to cause oesophagitis ADDIN EN.CITE ,  with prospective studies finding an increased risk of oesophageal injury and ulceration ADDIN EN.CITE 20, and case reports demonstrating tetracycline induced lesions. HYPERLINK \l "_ENREF_21" \o "Tahan, 2008 #85"  ADDIN EN.CITE <EndNote><Cite><Author>Tahan</Author><Year>2008</Year><RecNum>85</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1476871174">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Tahan, Veysel</author><author>Sayrak, Hakan</author><author>Bayar, Nevzat</author><author>Erer, Burak</author><author>Tahan, Gulgun</author><author>Dane, Faysal</author></authors></contributors><titles><title>Doxycycline-induced ulceration mimicking esophageal cancer</title><secondary-title>Cases Journal</secondary-title></titles><periodical><full-title>Cases J</full-title><abbr-1>Cases journal</abbr-1></periodical><pages>144-144</pages><volume>1</volume><dates><year>2008</year><pub-dates><date>09/08&#xD;07/19/received&#xD;09/08/accepted</date></pub-dates></dates><publisher>BioMed Central</publisher><isbn>1757-1626</isbn><accession-num>PMC2553052</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553052/</url><url>http://download.springer.com/static/pdf/153/art%253A10.1186%252F1757-1626-1-144.pdf?originUrl=http%3A%2F%2Fcasesjournal.biomedcentral.com%2Farticle%2F10.1186%2F1757-1626-1-144&amp;token2=exp=1476873988~acl=%2Fstatic%2Fpdf%2F153%2Fart%25253A10.1186%25252F1757-1626-1-144.pdf*~hmac=1ac6aed8afe53696448226135f1af6f2d0e6fd43d6c96c4ff99d32cf804908a3</url></related-urls></urls><electronic-resource-num>10.1186/1757-1626-1-144</electronic-resource-num><remote-database-name>PMC</remote-database-name></record></Cite></EndNote>21  Similarly, spironolactone has been associated with inflammation of the stomach including increased risk of gastric ulcers ADDIN EN.CITE 22, possibly due to impaired mucosal healing.  ADDIN EN.CITE ,  Despite the widespread and prolonged use of these medications, epidemiological studies have focussed solely on bisphosphonates and gastro-oesophageal cancer risk HYPERLINK \l "_ENREF_24" \o "Wright, 2015 #24"  ADDIN EN.CITE <EndNote><Cite><Author>Wright</Author><Year>2015</Year><RecNum>24</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1475681677">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wright, Ellen</author><author>Schofield, Peter T</author><author>Molokhia, Mariam</author></authors></contributors><titles><title>Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis</title><secondary-title>BMJ Open</secondary-title></titles><periodical><full-title>BMJ Open</full-title></periodical><volume>5</volume><number>12</number><dates><year>2015</year><pub-dates><date>December 1, 2015</date></pub-dates></dates><urls><related-urls><url>http://bmjopen.bmj.com/content/5/12/e007133.abstract</url><url>http://bmjopen.bmj.com/content/5/12/e007133.full.pdf</url></related-urls></urls><electronic-resource-num>10.1136/bmjopen-2014-007133</electronic-resource-num></record></Cite></EndNote>24, and have yet to investigate the risk associated with tetracyclines and spironolactone use.






We conducted a nested case-control study using the Primary Care Clinical Information Unit Research (PCCIUR) database. HYPERLINK \l "_ENREF_25" \o "The Institute of Applied Health Sciences, 2016 #86"  ADDIN EN.CITE <EndNote><Cite><Author>The Institute of Applied Health Sciences</Author><Year>2016</Year><RecNum>86</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1478104706">86</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>The Institute of Applied Health Sciences,</author></authors></contributors><titles><title>PCCIU Background</title></titles><dates><year>2016</year></dates><urls><related-urls><url>http://www.abdn.ac.uk/iahs/research/primary-care/pcciur/background.php</url></related-urls></urls><custom1>2016</custom1><custom2>02/11/16</custom2></record></Cite></EndNote>25 Between 1993 and 2011, the PCCIUR collected computerised medical records from approximately 15% of the Scottish general practice population, and includes details on patient demographics (e.g. age, deprivation), primary care encounters, clinical diagnoses and prescriptions. Access to the PCCIUR data was approved by the Research Applications and Data Management Team, University of Aberdeen. Ethical approval for this study was supplied by the Queen’s University Belfast, School of Medicine Ethics Committee (reference number: 15.43).
Cases and controls
Our primary outcome was gastro-oesophageal cancer since classifying tumours arising close to the oesophagogastric junction is difficult, and guidance on this process evolved throughout the study period. ADDIN EN.CITE ,  However, separate site-specific estimates for oesophageal and gastric cancer were also presented. Cases were defined as patients with a first-time oesophageal (Read code: B10..) or gastric (Read code: B11..) cancer diagnosis after 1st January 1999 and before 30th April 2011. Up to five controls were randomly selected for each case matched on age, gender, year of diagnosis and general practice. The index date was defined as the diagnosis date of the case in each matched group.  The start of the exposure period was the latest of 1st January 1996 (as prescriptions before this were less likely to be generated electronically) or the date of general practice registration.  Additionally, the exposure period was truncated to ensure it was identical across the matched groups. ADDIN EN.CITE 28 Cases and controls with an earlier cancer diagnosis (other than non-melanoma skin cancer), and those with less than three years of exposure prior to index date, were excluded from the matching process.
Definition of exposure
We identified prescriptions of bisphosphonates, tetracyclines and spironolactone from electronic prescription records. We used the British National Formulary (August 2016 version) to compile a list of proprietary and generic drug names containing these compounds (Appendix 1). We excluded prescriptions before 1st January 1996 and those in the year prior to the index date (to prevent reverse causation). We defined patients as users if they had at least one prescription during the exposure period. To enable the testing of dose-response relationships we calculated the total number of prescriptions received during the exposure period and split patients into lower (less than the median) and higher (more than the median) users. We conducted a separate analysis for nitrogen-containing bisphosphonates, as these have a mechanism of action distinct from non-nitrogen containing products HYPERLINK \l "_ENREF_29" \o "Drake, 2008 #89"  ADDIN EN.CITE <EndNote><Cite><Author>Drake</Author><Year>2008</Year><RecNum>89</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1478196073">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Drake, Matthew T.</author><author>Clarke, Bart L.</author><author>Khosla, Sundeep</author></authors></contributors><titles><title>Bisphosphonates: Mechanism of Action and Role in Clinical Practice</title><secondary-title>Mayo Clinic proceedings. Mayo Clinic</secondary-title></titles><periodical><full-title>Mayo Clinic proceedings. Mayo Clinic</full-title></periodical><pages>1032-1045</pages><volume>83</volume><number>9</number><dates><year>2008</year></dates><isbn>0025-6196&#xD;1942-5546</isbn><accession-num>PMC2667901</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667901/</url></related-urls></urls><remote-database-name>PMC</remote-database-name></record></Cite></EndNote>29, and alendronate, which has been previously linked to cases of esophageal cancer. HYPERLINK \l "_ENREF_30" \o "Wysowski , 2009 #19"  ADDIN EN.CITE <EndNote><Cite><Author>Wysowski</Author><Year>2009</Year><RecNum>19</RecNum><DisplayText><style face="superscript">30</style></DisplayText><record><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1475674497">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wysowski , Diane K.</author></authors></contributors><titles><title>Reports of Esophageal Cancer with Oral Bisphosphonate Use</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>89-90</pages><volume>360</volume><number>1</number><dates><year>2009</year></dates><accession-num>19118315</accession-num><urls><related-urls><url>http://www.nejm.org/doi/full/10.1056/NEJMc0808738</url><url>http://www.nejm.org/doi/pdf/10.1056/NEJMc0808738</url></related-urls></urls><electronic-resource-num>doi:10.1056/NEJMc0808738</electronic-resource-num></record></Cite></EndNote>30
Confounding factors
We identified eleven comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease, liver disease) using Read codes recorded by the GP during the exposure period. HYPERLINK \l "_ENREF_31" \o "Khan, 2010 #92"  ADDIN EN.CITE <EndNote><Cite><Author>Khan</Author><Year>2010</Year><RecNum>92</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1482158381">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Khan, Nada F.</author><author>Perera, Rafael</author><author>Harper, Stephen</author><author>Rose, Peter W.</author></authors></contributors><titles><title>Adaptation and validation of the Charlson Index for Read/OXMIS coded databases</title><secondary-title>BMC Family Practice</secondary-title></titles><periodical><full-title>BMC Family Practice</full-title></periodical><pages>1-1</pages><volume>11</volume><dates><year>2010</year><pub-dates><date>01/05&#xD;09/23/received&#xD;01/05/accepted</date></pub-dates></dates><publisher>BioMed Central</publisher><isbn>1471-2296</isbn><accession-num>PMC2820468</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820468/</url></related-urls></urls><electronic-resource-num>10.1186/1471-2296-11-1</electronic-resource-num><remote-database-name>PMC</remote-database-name></record></Cite></EndNote>31 Use of aspirin and statins within the exposure period were identified from prescription records (Appendix 1) as associations with oesophageal and/or gastric cancer have been identified previously. ADDIN EN.CITE ,  Lifestyle data including obesity (BMI>30), smoking status (never, ex, current) and alcohol use (none, low [e.g. moderate or light drinker], high [e.g. above recommended limits, chronic alcoholism]) were also recorded in the PCCIUR data using Read codes. 
Statistical Analysis
We calculated descriptive statistics and compared the demographics and clinical characteristics of the cases and controls. We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between medication use and gastro-oesophageal cancer.  The matched design of the study accounted for the effect of age, gender, general practice and year of diagnosis with additional adjustments were made for statin use (yes/no), aspirin use (yes/no) and the presence of each comorbidity (yes/no) using regression. 





We identified 3,098 cases of gastro-oesophageal cancer (1,979 oesophageal and 1,119 gastric cancer) (Table 1). An average of 4.8 controls existed for each case with a median exposure period of 5.5 years (min 3.0, max 15.1). There were some potentially important differences between cases and controls. Most notably, a larger proportion of cases had a history of COPD (11.7% vs 8.5%), and were more likely to be current or ex-smokers (64.7% vs 55.3%), drink high levels of alcohol (7.5% vs. 5.3%) and have a BMI under thirty (85.8% vs 79.9%). The proportion of missing data for smoking status and alcohol consumption was 21.5% and 32.0% respectively. 

Overall, 3.9% (122/3098) of cases and 3.5% (526/14937) of controls used bisphosphonates suggesting little association between bisphosphonate use and gastro-oesophageal cancer risk (ORadj= 1.05; 95% CI: 0.85, 1.31) (Table 2).  There was evidence of a 34% increased risk (ORadj= 1.34; 95% CI: 1.03, 1.74) of oesophageal cancer in bisphosphonate users but a reduction of 29% (ORadj= 0.71; 95% CI: 0.49, 1.03) in gastric cancer.  The association between bisphosphonate use and oesophageal or gastric cancer did not appear to follow a dose-response relationship.

Tetracycline was used by 6.0% (186/3098) of cases and 6.0% (894/14937) of controls; there was no evidence of association with gastro-oesophageal cancer risk (ORadj= 0.99; 95% CI: 0.84, 1.17). Similarly, little associations were observed between tetracycline use and oesophageal (ORadj= 1.01; 95% CI: 0.82, 1.25) and gastric cancer (ORadj= 0.96; 95% CI: 0.73, 1.28). 

Overall, 1.4% (43/3098) of cases and 1.1% (159/14937) of controls used spironolactone but there were small associations with gastro-oesophageal cancer risk after adjustment for confounders (ORadj= 1.04; 95%: 0.73, 1.49). Again, there was little evidence of higher risk for oesophageal or gastric cancer alone, with adjusted odds ratios of 1.04 (95% CI: 0.68, 1.61) and 1.05 (95% CI: 0.55, 2.00) respectively.






In this study of oesophageal and gastric cancer cases and controls in a community-based population, we found little evidence of an association between gastro-oesophageal cancer risk and the use of bisphosphonates, tetracyclines or spironolactone. Although there was some evidence that bisphosphonates increased the risk of oesophageal cancer, there was no obvious dose-response relationship and these increases were largely offset by a reduction in gastric cancer risk.
Strengths and limitations
The main strength of our study lies in the high-quality and nationally representative data on which it is based. HYPERLINK \l "_ENREF_36" \o "Elder, 2007 #13"  ADDIN EN.CITE <EndNote><Cite><Author>Elder</Author><Year>2007</Year><RecNum>13</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1475075817">13</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Elder, R.</author><author>Kirkpatrick, M.</author><author>Ramsay, W.</author><author>Macleod, M.</author><author>Guthrie, B.</author><author>Sutton, M.</author><author>Watt, G. </author></authors></contributors><titles><title>Measuring quality in primary medical services using data from SPICE</title></titles><dates><year>2007</year></dates><urls></urls></record></Cite></EndNote>36  It is the first study to investigate the effect of tetracycline and spironolactone on gastro-oesophageal cancer risk and has found no evidence of an increased incidence, which is important and reassuring given the large numbers of patients who use these medications often for prolonged periods of time. We used prescribing data collected as part of routine clinical care, in many cases, several years before the onset of oesophageal or gastric cancer which accurately reflects GP prescribing practices and negates the risk of recall bias.  Although a weakness of this approach is that we do not know if patients used their prescribed medications, the main conclusions were similar when restricting our analysis to patients who received multiple repeat prescriptions  (>12) where non-compliance is likely to be less of an issue. Additionally, GP records do not contain data on over-the-counter medications which may have impaired our ability to accurately adjust for aspirin use (due to exposure misclassification).

Our study is observational and hence open to confounding; although we have controlled for several of the key determinants of cancer risk through the matched design and analysis (e.g. age, comorbidities and general practice) some other risk factors, including ethnicity and nutrition, were not available. This could be a particular concern in the bisphosphonate analysis, as patients with osteoporosis may be more likely to report upper gastrointestinal disorders, even prior to bisphosphonate initiation. ADDIN EN.CITE 37 Our analysis is based on GP diagnosed cancer.  Although a recent CPRD study found that over 95% of gastro-oesophageal cancers are captured within GP records ADDIN EN.CITE 38, a higher proportion of oesophageal cancers were recorded in the Scottish Cancer Registry HYPERLINK \l "_ENREF_39" \o "(Scotland),  #91"  ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>(Scotland)</Author><RecNum>91</RecNum><DisplayText><style face="superscript">39</style></DisplayText><record><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="9asrdv5d8wrrwsep2wevezpo5209209ddvwt" timestamp="1478278972">91</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Information Services Division (Scotland)</author></authors></contributors><titles><title>Cancer Statistics</title></titles><volume>2016</volume><number>04/11/2016</number><dates></dates><urls><related-urls><url>http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/</url></related-urls></urls><custom1>2016</custom1><custom2>04/11/2016</custom2></record></Cite></EndNote>39 than the PCCIUR data, which could suggest some misclassification of cancer site in our study. This potential issue would not affect our primary analysis which combined oesophageal and gastric cancers. Finally, histological data were not available to allow a separate analysis of squamous cell carcinoma and adenocarcinoma, the two most common forms of oesophageal cancer.

Comparisons with other research
To our knowledge, this is the first study to investigate the impact of tetracyclines and spironolactone use on gastro-oesophageal cancer risk. 
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Implications
Bisphosphonate, tetracycline and spironolactone are widely used and effective treatments for a range of indications including osteoporosis, infections/acne/rosacea and hypertension/cardiac failure respectively. Our study suggests that any inflammation caused by these medications does not substantially increase the risk of gastro-oesophageal cancer, and GPs or patients should not be unduly concerned about cancer risk when prescribing or taking these treatments.
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Tables and Figures
Table 1: Characteristics of controls and cases with oesophageal or gastric cancer
	Cases	Controls
Count	3,098	14,937
























Not Obese	2,658 (85.8%)	11,932 (79.9%)
Obese	440 (14.2%)	3,005 (20.1%)
Deprivation Quintile		




5 (Most Deprived)	734 (24.0%)	3,549 (24.1%)
Missing	38	181
Common Comorbidities​[1]​		












Table 2: Combined analysis of drug use risk with oesophageal and gastric cancer risk




Ever	122 (3.9%)	526 (3.5%)	1.09 (0.88,1.34)	1.05 (0.85,1.31)
Lower Usage (1-18 prescriptions)	64 (2.1%)	249 (1.7%)	1.22 (0.92,1.61)	1.16 (0.87,1.55)
Higher Usage (19+)	58 (1.9%)	277 (1.9%)	0.97 (0.72,1.31)	0.95 (0.71,1.29)
Tetracycline				
Never	2,912 (94.0%)	14,043 (94.0%)	Ref	Ref
Ever	186 (6.0%)	894 (6.0%)	1.01 (0.86,1.20)	0.99 (0.84,1.17)
Lower Usage (1)	104 (3.4%)	542 (3.6%)	0.93 (0.75,1.16)	0.92 (0.74,1.14)
Higher Usage (2+)	82 (2.6%)	352 (2.4%)	1.14 (0.89,1.45)	1.10 (0.86,1.42)
Spironolactone				
Never	3,055 (98.6%)	14,778 (98.9%)	Ref	Ref
Ever	43 (1.4%)	159 (1.1%)	1.24 (0.88,1.75)	1.04 (0.73,1.49)
Lower Usage (1-10)	21 (0.7%)	77 (0.5%)	1.26 (0.77,2.05)	1.10 (0.67,1.81)




Ever	84 (4.2%)	289 (3.0%)	1.40 (1.08,1.81)	1.34 (1.03,1.74)
Lower Usage (1-18)	47 (2.4%)	127 (1.3%)	1.78 (1.25,2.51)	1.70 (1.20,2.43)
Higher Usage (19+)	37 (1.9%)	162 (1.7%)	1.09 (0.75,1.58)	1.04 (0.71,1.52)
Tetracycline				
Never	1,858 (93.9%)	8,976 (94.1%)	Ref	Ref
Ever	121 (6.1%)	567 (5.9%)	1.04 (0.85,1.29)	1.01 (0.82,1.25)
Lower Usage (1)	66 (3.3%)	341 (3.6%)	0.95 (0.72,1.24)	0.93 (0.70,1.22)
Higher Usage (2+)	55 (2.8%)	226 (2.4%)	1.19 (0.88,1.61)	1.14 (0.83,1.55)
Spironolactone				
Never	1,949 (98.5%)	9,436 (98.9%)	Ref	Ref
Ever	30 (1.5%)	107 (1.1%)	1.27 (0.84,1.92)	1.04 (0.68,1.61)
Lower Usage (1-10)	13 (0.7%)	55 (0.6%)	1.05 (0.57,1.95)	0.94 (0.50,1.75)




Ever	38 (3.4%)	237 (4.4%)	0.72 (0.50,1.04)	0.71 (0.49,1.03)
Lower Usage (1-18)	17 (1.5%)	122 (2.3%)	0.65 (0.39,1.08)	0.62 (0.37,1.04)
Higher Usage (19+)	21 (1.9%)	115 (2.1%)	0.80 (0.49,1.29)	0.80 (0.49,1.31)
Tetracycline				
Never	1,054 (94.2%)	5,067 (93.9%)	Ref	Ref
Ever	65 (5.8%)	327 (6.1%)	0.96 (0.72,1.27)	0.96 (0.73,1.28)
Lower Usage (1)	38 (3.4%)	201 (3.7%)	0.90 (0.63,1.29)	0.92 (0.64,1.31)
Higher Usage (2+)	27 (2.4%)	126 (2.3%)	1.04 (0.68,1.59)	1.04 (0.68,1.59)
Spironolactone				
Never	1,106 (98.8%)	5,342 (99.0%)	Ref	Ref
Ever	13 (1.2%)	52 (1.0%)	1.18 (0.63,2.21)	1.05 (0.55,2.00)
Lower Usage (1-10)	8 (0.7%)	22 (0.4%)	1.78 (0.78,4.08)	1.53 (0.66,3.57)




Table 3: Sensitivity analysis
	Cases	Controls	Unadjusted OR(95% CI)	Adjusted OR(95% CI)​[3]​
Bisphosphonates
2- year exposure lag				
Never	3,001 (96.9%)	14,520 (97.2%)	Ref	Ref
Ever	97 (3.1%)	417 (2.8%)	1.09 (0.86,1.37)	1.04 (0.82,1.33)
Ever use ≥3 prescriptions				
Never	2,988 (96.4%)	14,442 (96.7%)	Ref	Ref
Ever	110 (3.6%)	495 (3.3%)	1.05 (0.84,1.30)	1.01 (0.81,1.26)
MI​[4]​ lifestyle adjusted				
Never	2,976 (96.1%)	14,411 (96.5%)	Ref	Ref
Ever	122 (3.9%)	526 (3.5%)	1.09 (0.88,1.34)	1.03 (0.83,1.28)
Lifestyle complete case				
Never	2,123 (96.0%)	9,218 (96.2%)	Ref	Ref
Ever	88 (4.0%)	369 (3.8%)	1.00 (0.77,1.29)	0.93 (0.71,1.21)
Nitrogen containing bisphosphonates	
Never	3,001 (96.9%)	14,551 (97.4%)	Ref	Ref
Ever	97 (3.1%)	386 (2.6%)	1.18 (0.93,1.50)	1.15 (0.90,1.46)
Alendronate only				
Never	3,015 (97.3%)	14,603 (97.8%)	Ref	Ref
Ever	83 (2.7%)	334 (2.2%)	1.17 (0.91,1.51)	1.13 (0.87,1.46)
Tetracycline
2- year exposure lag				
Never	2,933 (94.7%)	14,200 (95.1%)	Ref	Ref
Ever	165 (5.3%)	737 (4.9%)	1.10 (0.92,1.31)	1.07 (0.89,1.28)
Ever use ≥3 prescriptions				
Never	3,049 (98.4%)	14,718 (98.5%)	Ref	Ref
Ever	49 (1.6%)	219 (1.5%)	1.10 (0.80,1.50)	1.05 (0.76,1.45)
MI lifestyle adjusted				
Never	2,912 (94.0%)	14,043 (94.0%)	Ref	Ref
Ever	186 (6.0%)	894 (6.0%)	1.01 (0.86,1.20)	1.02 (0.86,1.20)
Lifestyle complete case				
Never	2,067 (93.5%)	8,914 (93.0%)	Ref	Ref
Ever	144 (6.5%)	673 (7.0%)	0.93 (0.76,1.13)	0.92 (0.75,1.13)
Spironolactone
2- year exposure lag				
Never	3,069 (99.1%)	14,805 (99.1%)	Ref	Ref
Ever	29 (0.9%)	132 (0.9%)	1.02 (0.68,1.53)	0.82 (0.54,1.26)
Ever use ≥3 prescriptions				
Never	3,061 (98.8%)	14,802 (99.1%)	Ref	Ref
Ever	37 (1.2%)	135 (0.9%)	1.26 (0.87,1.83)	1.05 (0.72,1.54)
MI lifestyle adjusted				
Never	3,055 (98.6%)	14,778 (98.9%)	Ref	Ref
Ever	43 (1.4%)	159 (1.1%)	1.24 (0.88,1.75)	1.09 (0.76,1.57)
Lifestyle complete case				
Never	2,175 (98.4%)	9,478 (98.9%)	Ref	Ref




Appendix 1: List of generic and proprietary drug names for each exposure and confounder medication
Substance Name	Drug Name
Aspirin	Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals
Bisphosphonates	Aclasta, Actonel, Alendronic acid, Aredia, Binosto, Bondronat, Bonefos, Bonviva, Clasteon, Clodronate, Didronel, Didronel PMO, Fosamax, Fosavance, Iasibon, Ibrandronic acid, Loron, Pamidronate, Risedronate, Zoledronic acid, Zometa
Spironolactone	Aldactide, Aldactone, Co-flumactone, Lasilactone, Spironolactone
Statin	Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, Simvastatin, Stefluvin, Zocor







^1	  For brevity only the 5 most common comorbidities are listed. The full analysis included myocardial infarction (MI), heart failure, peripheral vascular disease, cerebrovascular disease (CVD), connective tissue disease, dementia, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, diabetes, renal disease and liver disease
^2	  Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, general practice and year of diagnosis
^3	  Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, general practice and year of diagnosis
^4	  Multiple imputation with chained equations for smoking, alcohol consumption and obesity with age, gender and deprivation used in the imputation, separately for cases and controls, using chained ordered logit models
